| 摘要 |
Solid oral galenical form with prolonged release of molsidomine, intended for treating heart angina in its various forms, containing a therapeutically effective amount of molsidomine or one of its active metabolites and has following an in vitro dissolution rate [measured by spectrophotometry at 286 or 311 nm according to the European Pharmacopeia, third edition (or U. S. P. XXIV) at 50 revolutions per minute in 500 ml of a HCl 0.1N medium, at 37 °C]: 15 to 25 % of molsidomine released after 2 hour, 50 to 65 % of molsidomine released after 6 hours, 75 to 95 % of molsidomine released after 12 hours, > 85 % of molsidomine released after 18 hours and > 90 % of molsidomine released after 24 hours, whereby the plasma peak of molsidomine obtained in vivo occurring between 2.5 to 5 hours, preferably between 3 to 4 hours depending on the administration of said form and exhibiting a value between 25 and 40 ng/ml of plasma.
|
